Helomics

Helomics Corporation is a personalized healthcare company focused on oncology, providing innovative tools to assist physicians and patients in making informed decisions throughout the cancer care continuum. It has developed a Precision Cellular Analytical Platform that analyzes cellular data over a 25-35 day period. Among its key products are ChemoFx, which aids in selecting effective treatments for gynecologic cancer patients; BioSpeciFx, offering biomarker tests for evaluating tumor responses at the molecular level; and GeneFx products, which use gene signatures to inform treatment options for colon and lung cancer patients. Additionally, Helomics provides tumor profiling services, including bioinformatics and patient-derived tumor models, which enhance clinical research and drug development. The company employs artificial intelligence through its D-CHIP platform to create personalized oncology roadmaps for patients. Founded in 1995 and headquartered in Pittsburgh, Pennsylvania, Helomics operates as a subsidiary of Predictive Oncology Inc.